当前位置:首页 > 报告详情

在法国一项人工智能模拟模型概念验证框架研究预测了2.4毫克司美格鲁肽对真实人群体重变化的有效性.pdf

上传人: 表表 编号:1280001 2026-07-18 1页 289.32KB

1、Scan QR code or visit the web site below for:Digital posterhttps:/ CONSTANCES French national cohort.Available at:http:/doi.org/10.13143/inserm_constances(accessed May 2026);(2)Zins M,Goldberg M,and the CONSTANCES team.Eur J Epidemiology 2015;30:13171328;(3)Wilding JPH et al.N Engl J Med 2021;384:98

2、91002;(4)Davies M et al.Lancet 2021;397:971984;(5)Garvey WT et al.Nat Med2022;28:20832091;(6)European Medicines Agency.Available at:https:/www.ema.europa.eu/en/documents/overview/wegovy-epar-medicine-overview_en.pdf(accessed May 2026).1Department of Nutrition,Hpital Europen Georges Pompidou,Assistan

3、ce Publique-Hpitaux de Paris,Universit Paris Cit,Paris,France;2Department of Endocrinology Diabetes and Nutrition,Hpital Lyon Sud,Hospices Civils de Lyon,Universit Claude Bernard Lyon 1,Lyon,France;3Center for Clinical Research and Prevention,Copenhagen University Hospital-Bispebjerg and Frederiksbe

4、rg,Copenhagen,Denmark;4Novo Nordisk Health Care AG,Zrich,Switzerland;5Novo Nordisk,Puteaux,France;6Department of Endocrinology and Metabolism,Peking University Peoples Hospital,Beijing,China;7Department of Systems Medicine,University of Rome Tor Vergata and Obesity Medical Center,University Hospital

5、 Policlinico Tor Vergata,Rome,Italy;8Department of Metabolism and Endocrinology,Akita University Graduate School of Medicine,Akita,Japan;9Department of Medicine,Faculty of Medicine and Dentistry,University of Alberta,Edmonton,AB,Canada.This study was funded by Novo Nordisk A/S.The AI modelling frame

6、work development and data analysis were performed by Quinten Health.Medical writing support was provided by Carolyn Bowler,PhD,CMPP,of Apollo,OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(www.ismpp.org/gpp-2022).The authors than

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **研究目的**:基于AI框架模拟司美格鲁肽2.4mg在不同人群中的长期减重效果(法国人群)。 2. **数据来源**:整合法国真实世界队列(CONSTANCES)与随机对照试验(STEP 1/2/5)数据,纳入25,510名超重/肥胖患者(BMI≥30或≥27伴并发症)。 3. **核心结果**: - 总体减重:无T2D者(STEP 1)-14.9%,伴T2D者(STEP 2)-9.6%(68周)。 - 性别差异:女性无T2D减重更显著(-18.7% vs 男性-11.6%,104周)。 4. **结论**:AI模型可预测不同人群疗效,为个性化治疗提供依据。
**AI如何预测减肥效果?** **司美格鲁肽对不同人群有效吗?** **真实数据如何模拟药物疗效?**
客服
商务合作
小程序
服务号
折叠